Prothena FY2028 EPS Estimate Raised by HC Wainwright

Prothena Co. plc (NASDAQ:PRTA) – Equities research analysts at HC Wainwright raised their FY2028 earnings estimates for shares of Prothena in a report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $3.34 for the year, up from their prior estimate of $3.26. HC Wainwright currently has a “Buy” rating and a $84.00 target price on the stock. The consensus estimate for Prothena’s current full-year earnings is ($2.34) per share.

PRTA has been the subject of several other reports. Royal Bank of Canada dropped their price objective on Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. Bank of America cut their price target on shares of Prothena from $33.00 to $31.00 and set a “neutral” rating for the company in a report on Tuesday, October 1st. Oppenheimer reduced their price target on shares of Prothena from $66.00 to $62.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a report on Monday, September 30th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $61.86.

Prothena Trading Down 13.0 %

Shares of PRTA opened at $14.01 on Friday. The stock has a 50 day simple moving average of $18.19 and a 200-day simple moving average of $20.34. The stock has a market cap of $753.46 million, a PE ratio of -5.65 and a beta of 0.16. Prothena has a 1 year low of $14.00 and a 1 year high of $41.54.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The firm had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $1.22 million. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company’s revenue for the quarter was down 98.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.38 earnings per share.

Institutional Trading of Prothena

Several hedge funds have recently modified their holdings of PRTA. Signaturefd LLC lifted its holdings in Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock worth $28,000 after buying an additional 863 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Prothena during the first quarter valued at $96,000. China Universal Asset Management Co. Ltd. boosted its holdings in Prothena by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 4,026 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Prothena in the third quarter worth about $210,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Prothena by 13.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 1,186 shares during the period. 97.08% of the stock is owned by institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.